AR091259A1 - Formas solidas de un compuesto antiviral - Google Patents
Formas solidas de un compuesto antiviralInfo
- Publication number
- AR091259A1 AR091259A1 ARP130101956A AR091259A1 AR 091259 A1 AR091259 A1 AR 091259A1 AR P130101956 A ARP130101956 A AR P130101956A AR 091259 A1 AR091259 A1 AR 091259A1
- Authority
- AR
- Argentina
- Prior art keywords
- solid forms
- antiviral compound
- aza
- methyl
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicación 1: El solvato con diacetona del éster metílico del ácido (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-metoxicarbonilamino-3-metil-butiril)-5-aza-espiro[2.4]hept-6-il]-3H-imidazol-4-il}-9H-fluoren-2-il)-1H-benzimidazol-2-il]-2-aza-biciclo[2.2.1]heptano-2-carbonil}-2-metil-propil)carbámico cristalino (Forma I del compuesto de fórmula (1)) caracterizado porque tiene un difractograma de rayos X en polvo que comprende los siguientes picos: 6,8, 12,5, y 19,8 º2q ± 0,2 º2q, determinados con un difractómetro usando radiación Cu-Ka con una longitud de onda de 1,54178 Å.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261655934P | 2012-06-05 | 2012-06-05 | |
US201361759295P | 2013-01-31 | 2013-01-31 | |
US13/800,374 US8969588B2 (en) | 2012-06-05 | 2013-03-13 | Solid forms of an antiviral compound |
Publications (1)
Publication Number | Publication Date |
---|---|
AR091259A1 true AR091259A1 (es) | 2015-01-21 |
Family
ID=49670993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101956 AR091259A1 (es) | 2012-06-05 | 2013-06-03 | Formas solidas de un compuesto antiviral |
Country Status (20)
Country | Link |
---|---|
US (4) | US8969588B2 (es) |
EP (1) | EP2855478B1 (es) |
JP (2) | JP2015518891A (es) |
KR (1) | KR20150028971A (es) |
CN (2) | CN105524050A (es) |
AR (1) | AR091259A1 (es) |
AU (1) | AU2013271768B2 (es) |
BR (1) | BR112014030400A2 (es) |
CA (1) | CA2875507A1 (es) |
ES (1) | ES2694759T3 (es) |
HK (1) | HK1205127A1 (es) |
IL (1) | IL236004A0 (es) |
IN (1) | IN2014MN02644A (es) |
MX (1) | MX2014014563A (es) |
PT (1) | PT2855478T (es) |
RU (1) | RU2014150437A (es) |
SG (1) | SG11201408013WA (es) |
TW (1) | TW201408661A (es) |
UY (1) | UY34844A (es) |
WO (1) | WO2013184698A1 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1633766T (pt) | 2003-05-30 | 2019-06-04 | Gilead Pharmasset Llc | Análogos de nucleósido fluorado modificado |
DK2430014T3 (en) | 2009-05-13 | 2015-11-30 | Gilead Pharmasset Llc | Anti-viral compounds |
JP5934787B2 (ja) | 2011-05-10 | 2016-06-15 | ギリアード サイエンシーズ, インコーポレイテッド | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
SI2709613T2 (sl) | 2011-09-16 | 2020-12-31 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Postopki za zdravljenje HCV |
US9056860B2 (en) | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
SG11201506021XA (en) | 2013-01-31 | 2015-08-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
TW201446286A (zh) * | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
CN104211565A (zh) * | 2013-05-31 | 2014-12-17 | 浙江九洲药业股份有限公司 | 一种抗丙型肝炎药物中间体的制备方法 |
MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
CN104513223B (zh) * | 2014-11-20 | 2017-07-14 | 上海众强药业有限公司 | 芴乙酮衍生物的制备方法 |
CN107427495A (zh) | 2015-02-13 | 2017-12-01 | 桑多斯股份公司 | 包含雷迪帕韦和索非布韦的药物组合物 |
WO2016145269A1 (en) | 2015-03-12 | 2016-09-15 | Teva Pharmaceuticals International Gmbh | Solid state forms ledipasvir and processes for preparation of ledipasvir |
CN104788361B (zh) * | 2015-04-21 | 2017-06-30 | 杭州科巢生物科技有限公司 | 5‑氮杂螺[2.4]庚烷‑6‑甲酸衍生物的合成方法 |
WO2016193919A1 (en) | 2015-06-05 | 2016-12-08 | Mylan Laboratories Limited | Polymorphic form of ledipasvir |
CN104961733B (zh) * | 2015-07-06 | 2019-04-09 | 上海众强药业有限公司 | 雷迪帕韦晶型及其制备方法 |
WO2017072596A1 (en) | 2015-10-26 | 2017-05-04 | Optimus Drugs (P) Ltd | An improved process for the preparation of ledipasvir |
CN106608870A (zh) * | 2015-10-26 | 2017-05-03 | 广东东阳光药业有限公司 | 一种制备雷迪帕韦杂质的方法 |
WO2017072714A1 (en) | 2015-10-30 | 2017-05-04 | Lupin Limited | Stable ledipasvir premix and process of preparation thereof |
CN105237517B (zh) * | 2015-10-30 | 2017-10-27 | 南京正大天晴制药有限公司 | 结晶的雷迪帕韦化合物及其制备方法 |
CN105237384B (zh) * | 2015-11-06 | 2017-06-30 | 上海万溯化学有限公司 | 一种多取代芴衍生物的制备方法 |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
CN106008316B (zh) * | 2016-06-17 | 2018-04-27 | 成都百事兴科技实业有限公司 | 一种合成雷迪帕韦手性中间体的方法 |
CN111202744A (zh) * | 2016-12-26 | 2020-05-29 | 上海博志研新药物技术有限公司 | 一种雷迪帕韦和索非布韦复方片剂及其制备方法和应用 |
US10392370B2 (en) | 2017-03-13 | 2019-08-27 | Optimus Drugs Pvt Ltd | Process for the preparation of Daclatasvir dihydrochloride and its intermediates |
CN109053400A (zh) * | 2018-08-24 | 2018-12-21 | 江苏工程职业技术学院 | 一种雷迪帕韦关键中间体的制备方法 |
US11378965B2 (en) | 2018-11-15 | 2022-07-05 | Toyota Research Institute, Inc. | Systems and methods for controlling a vehicle based on determined complexity of contextual environment |
CN109678686A (zh) * | 2018-12-19 | 2019-04-26 | 江苏工程职业技术学院 | 一种抗丙肝药物雷迪帕韦关键中间体的制备方法 |
EP4341266A1 (en) | 2021-05-21 | 2024-03-27 | Gilead Sciences, Inc. | Pentacyclic derivatives as zika virus inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US6482847B2 (en) * | 2000-10-03 | 2002-11-19 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
WO2005021549A1 (en) * | 2003-08-28 | 2005-03-10 | Ranbaxy Laboratories Limited | Amorphous valganciclovir hydrochloride |
CN100448879C (zh) * | 2004-07-22 | 2009-01-07 | 北京化工大学 | 一种无定型头孢呋辛酯的制备方法 |
US20100076047A1 (en) * | 2007-08-20 | 2010-03-25 | Sankar Reddy Budidet | Amorphous 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate salt |
KR20100031045A (ko) * | 2008-09-11 | 2010-03-19 | 씨제이제일제당 (주) | 아데포비어 디피복실의 정제방법 |
DK2430014T3 (en) | 2009-05-13 | 2015-11-30 | Gilead Pharmasset Llc | Anti-viral compounds |
US20120135965A1 (en) * | 2009-05-20 | 2012-05-31 | Ranbaxy Laboratories Limited | Amorphous fosamprenavir calcium |
JPWO2011046182A1 (ja) * | 2009-10-16 | 2013-03-07 | 出光興産株式会社 | 含フルオレン芳香族化合物、有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子 |
TW201211047A (en) | 2010-06-10 | 2012-03-16 | Gilead Sciences Inc | Methods for treating HCV |
JP5781706B2 (ja) * | 2011-12-29 | 2015-09-24 | アッヴィ・アイルランド・アンリミテッド・カンパニー | Hcv阻害剤を含む固体組成物 |
US9056860B2 (en) | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
SG11201506021XA (en) * | 2013-01-31 | 2015-08-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
-
2013
- 2013-03-13 US US13/800,374 patent/US8969588B2/en active Active
- 2013-05-31 TW TW102119443A patent/TW201408661A/zh unknown
- 2013-06-03 AR ARP130101956 patent/AR091259A1/es unknown
- 2013-06-03 UY UY0001034844A patent/UY34844A/es not_active Application Discontinuation
- 2013-06-04 EP EP13729569.7A patent/EP2855478B1/en active Active
- 2013-06-04 PT PT13729569T patent/PT2855478T/pt unknown
- 2013-06-04 AU AU2013271768A patent/AU2013271768B2/en not_active Ceased
- 2013-06-04 CN CN201510929740.8A patent/CN105524050A/zh active Pending
- 2013-06-04 SG SG11201408013WA patent/SG11201408013WA/en unknown
- 2013-06-04 KR KR20147037165A patent/KR20150028971A/ko not_active Application Discontinuation
- 2013-06-04 CA CA2875507A patent/CA2875507A1/en not_active Abandoned
- 2013-06-04 RU RU2014150437A patent/RU2014150437A/ru not_active Application Discontinuation
- 2013-06-04 MX MX2014014563A patent/MX2014014563A/es unknown
- 2013-06-04 WO PCT/US2013/044138 patent/WO2013184698A1/en active Application Filing
- 2013-06-04 CN CN201380032193.2A patent/CN104379584A/zh active Pending
- 2013-06-04 BR BR112014030400A patent/BR112014030400A2/pt not_active Application Discontinuation
- 2013-06-04 ES ES13729569.7T patent/ES2694759T3/es active Active
- 2013-06-04 IN IN2644MUN2014 patent/IN2014MN02644A/en unknown
- 2013-06-04 JP JP2015516143A patent/JP2015518891A/ja active Pending
-
2014
- 2014-11-30 IL IL236004A patent/IL236004A0/en unknown
-
2015
- 2015-01-20 US US14/600,911 patent/US9139570B2/en active Active
- 2015-06-23 HK HK15105959.1A patent/HK1205127A1/xx unknown
- 2015-08-13 US US14/825,386 patent/US9682987B2/en active Active
-
2017
- 2017-04-19 JP JP2017083097A patent/JP2017128605A/ja active Pending
- 2017-05-26 US US15/607,326 patent/US20170327488A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2694759T3 (es) | 2018-12-27 |
JP2017128605A (ja) | 2017-07-27 |
AU2013271768A1 (en) | 2015-01-15 |
US20150141659A1 (en) | 2015-05-21 |
EP2855478A1 (en) | 2015-04-08 |
JP2015518891A (ja) | 2015-07-06 |
US20150344488A1 (en) | 2015-12-03 |
IL236004A0 (en) | 2015-02-01 |
KR20150028971A (ko) | 2015-03-17 |
PT2855478T (pt) | 2018-11-21 |
TW201408661A (zh) | 2014-03-01 |
BR112014030400A2 (pt) | 2016-06-07 |
SG11201408013WA (en) | 2015-01-29 |
UY34844A (es) | 2013-12-31 |
US9139570B2 (en) | 2015-09-22 |
HK1205127A1 (en) | 2015-12-11 |
CA2875507A1 (en) | 2013-12-12 |
WO2013184698A1 (en) | 2013-12-12 |
EP2855478B1 (en) | 2018-08-08 |
RU2014150437A (ru) | 2016-08-10 |
CN105524050A (zh) | 2016-04-27 |
AU2013271768B2 (en) | 2018-05-17 |
MX2014014563A (es) | 2015-07-06 |
US20170327488A1 (en) | 2017-11-16 |
US20130324496A1 (en) | 2013-12-05 |
US9682987B2 (en) | 2017-06-20 |
IN2014MN02644A (es) | 2015-10-16 |
CN104379584A (zh) | 2015-02-25 |
US8969588B2 (en) | 2015-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR091259A1 (es) | Formas solidas de un compuesto antiviral | |
UY34261A (es) | Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-2-ciclil-etil}-1h-[1,2,4]triazol sustituidos | |
PE20171105A1 (es) | Formas solidas de un inhibidor ask1 | |
AR096582A1 (es) | Procesos de fabricación y formas cristalinas de un inhibidor de mdm2 | |
PE20140252A1 (es) | ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf | |
CU24462B1 (es) | Derivados de feniltriazol sustituido con hidroxialquilo | |
CR20140378A (es) | Derivados de pirido[2,3-d] pirimidina sustituidos con 2-amino, 6-fenilo útiles como inhibidores de cinasa raf | |
GT201200332A (es) | Composiciones sòlidas | |
CL2016000292A1 (es) | Formas de dosificación de liberación prolongada para un inhibidor de jak 1 | |
CR20160099A (es) | Formulación de inhibidores de la syk | |
CO6900158A2 (es) | Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-aluiniloxi-etil}-1h-[1,2,4]triazol sustituidos | |
SV2009003406A (es) | Compuestos organicos | |
SV2011003853A (es) | Compuestos organicos | |
AR102171A1 (es) | Compuestos sustituidos de aminopurina, sus composiciones y su uso en el tratamiento o prevención de melanoma | |
CR11757A (es) | Compuestos de triazina como inhibidores mtor y quinasa pi3 | |
EP2550266A4 (en) | HETEROCYCLIC COMPOUNDS FOR KINASE INHIBITION | |
CL2011003022A1 (es) | Compuestos derivados de 2,4 diaminopirimidina, inhibidores de quinasa ptk2; composicion farmaceutica que comprende a uno de los compuestos, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva, tal como cancer. | |
CO7111292A2 (es) | Derivados cíclicos de diaminopirimidina | |
AR092121A1 (es) | Formas solidas de un compuesto antiviral | |
CL2016000496A1 (es) | Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias. | |
CU24630B1 (es) | Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina | |
DOP2016000021A (es) | Imidazotiazol sulfonamidas como nematicidas | |
HN2009001330A (es) | Compuestos novedosos activos como antagonistas de receptore muscarinico | |
CR20150041A (es) | Azaheterociclos como inhibidores de bir2 y/o bir3 | |
PE20160884A1 (es) | Acetato de 4-{4-[(1e)-4-(2,9-diazaespiro[5.5]undec-2-il)but-1-en-1-il]-2-metilbencil}-5-(propan-2-il)-1h-pirazol-3-ilo beta-d-glucopiranosido |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |